A condensed, three-question version of the Patient Health Questionnaire-9 (PHQ-9), known as the PHQ-3, may offer clinicians a faster, yet reliable, method for detecting depression. Research involving more than 96,000 U.S. adults demonstrated that the PHQ-3 achieved 98% sensitivity and 76% specificity in identifying moderate to severe depressive symptoms.
The PHQ-3 also showed strong correlation with the full PHQ-9 and performed comparably to a recently validated four-item version, achieving over 90% sensitivity across all age, racial, and ethnic groups.
Lead Researcher Comments on Study Design
Dr. Roy H. Perlis, vice chair of research in the Department of Psychiatry at Mass General Brigham in Boston, explained that the team sought the shortest PHQ-9 version that could still effectively screen for depression. “We let the data tell us what the constellation of symptoms best predicts overall severity and how well they identify depression. It’s a way to obtain maximum information in minimal time,” he told Medscape Medical News.
Although results are promising, Perlis cautioned that the PHQ-3 is not yet ready for widespread clinical use. “Further studies in clinical settings are needed, but this study is a strong first step in demonstrating efficacy in a broad U.S. adult sample,” he said. The findings were published online on July 21 in JAMA Network Open.
Challenges of Longer Questionnaires
While the PHQ-9 is a valuable tool for initiating conversations about depression, anxiety, and related conditions, its length has proven burdensome for some patients. Long questionnaires can lead to incomplete responses or rushed answers, particularly among users of mobile apps.
At the recent American Psychiatric Association annual meeting, clinicians noted that many patients preferred shorter surveys. Perlis emphasized that shorter attention spans and demand for rapid results motivated the research. “The question was whether we could ask fewer questions and achieve nearly the same accuracy as the full PHQ-9,” he said.
Study Design and Participant Demographics
The researchers analyzed four waves of online survey data collected from November 2023 to July 2024, totaling 96,234 participants (57% women; mean age 47.3 years). The racial and ethnic composition included 68% White, 13% Black, 10% Hispanic or Latino, 5% Asian, and 4% classified as other. In the full sample, 26% exhibited moderate or greater depressive symptoms (PHQ-9 ≥ 10).
Identifying the Optimal Three Questions
After testing shortened PHQ-9 versions ranging from one to eight items, the PHQ-3—comprising items 1 (interest), 2 (depressed mood), and 6 (self-esteem/failure)—emerged as the optimal combination. It demonstrated a sensitivity of 0.98 (95% CI, 0.97-0.98) and a specificity of 0.76 (95% CI, 0.75-0.76) for detecting moderate or greater depressive symptoms.
Sensitivity exceeded 0.94 across all subgroups except participants aged 65 and older, where it was 0.93. The PHQ-3 also proved noninferior to the four-item PHQ in terms of sensitivity and specificity. The area under the receiver operating characteristic curve (AUROC) was 0.83 for the PHQ-3 and 0.84 for the PHQ-9.
Clinical Implications and Follow-Up
The PHQ-3 could serve as an initial screening tool, with additional questions administered as needed. Perlis emphasized that the most crucial step is follow-up: “People need to screen for depression, and if positive, a more comprehensive evaluation and treatment plan should be offered.”
Expert Editorial Perspective
Dr. Kurt Kroenke of the Regenstrief Institute highlighted both strengths and limitations of the study. Strengths include the large, diverse population; limitations include the absence of structured psychiatric interviews for validating sensitivity and specificity. Kroenke noted that ultrashort depression measures, including the two- and four-item Patient-Reported Outcomes Measurement Information System (PROMIS) versions, also show benefit. “Clinicians and researchers now have a menu of short depression measures to choose from,” he said.
Conclusion
While the PHQ-3 shows promise, additional research is required in clinical and primary care settings to confirm its efficacy. Shortened screening tools could improve accessibility and reduce participant burden, potentially facilitating earlier identification and treatment of depression.
Related topics
